Open access
10 July 2012

The Triple Threat of Cryptococcosis: It’s the Body Site, the Strain, and/or the Host

ABSTRACT

Cryptococcosis is the leading invasive fungal infection in the world today. Over the past century, the causative agents, Cryptococcus neoformans and Cryptococcus gattii, have risen from the status of medical curiosities to common but life-threatening central nervous system pathogens. In an elegant experimental pathobiology study of these two organisms carried out by Ngamskulrungroj et al., there are three matters that merit further discussion. First is the question of whether there is a variable specific pathobiology for each yeast strain. Does it make biological and clinical sense to designate C. neoformans and C. gattii as two separate species? Second is the matter of how the organisms differ pathologically at the site of infection. Finally, there is the possibility that the human immune system responds differently to each species. Although no single study can provide definitive mechanistic answers to the important questions, this experimental pathology study and its discussion clearly frame the issues to be dissected.

Commentary

In their study, “The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model,” Ngamskulrungroj et al. (1) found that a C. gattii strain grew well in the murine lung but was inefficient at leaving the lung and producing disease in the brain. A C. neoformans strain, on the other hand, easily left its original site of infection and, with its known cerebral tropism, caused severe disease in the brains of mice. Mechanistically, the causes of these differences remain uncertain. This study clearly emphasizes that there are differences between these cryptococcal species despite their phylogenetic and phenotypic relatedness. Are the differences between C. neoformans and C. gattii significant, and how do these differences relate to the site of infection each favors and the human host immune responses they elicit?
As to the question of their differences, from a clinical standpoint, anything C. neoformans can do, C. gattii can do also. Their respective diseases overlap. However, the perception of many investigators and clinicians is that C. gattii infects primarily immunocompetent hosts whereas C. neoformans causes disease primarily in immunocompromised patients. Furthermore, C. gattii tends to produce larger granulomas or cryptococcomas in the lung and brain than does C. neoformans. Clinical differences between the two species’ disease production are created by complex interactions influenced by the differences in ecology, epidemiology, biology of the strain, and host factors (2). The pathobiology of the two species reveals more differences. For example, the genomes of the two species show distinct sequence differences (3, 4) and molecular pathogenesis studies have revealed functional differences between similar genes in the two species. Disruption of the trehalose synthase gene (tpsI) in C. neoformans and C. gattii, for instance, creates null mutants that survive high mammalian temperatures and are avirulent in mammals, but a ΔtpsI mutant of C. gattii had poor capsule and melanin formation, whereas a ΔtpsI mutant of C. neoformans had no change in these prominent virulence factors (5). Hence, the genetic networks are not exactly the same.
Of course, the total virulence composites of individual strains of both C. neoformans and C. gattii are variable. In fact, C. neoformans strains and even C. gattii strains that are very closely related can have widely different transcriptional circuits and phenotypic differences in virulence when carefully analyzed in controlled murine models of infection (6). Therefore, microevolution is clearly present in these two species, and even recently, recombinant strains within a species, such as the C. gattii Vancouver (genotype VGII) outbreak strains, have evolved into new ecological sites and changed their virulence composites (7). It is an important concept for all who study these yeasts to remember that the plasticity of the cryptococcal genome and its epigenetic factors can be measured on a real-time basis within strains and species. This adaptability helps to explain how they survive stresses. We are just beginning to see how this genetic variation or plasticity among and within cryptococcal strains occurs (8, 9) and the role that microevolution of disease plays in drug resistance (10, 11). Thus, it would be naive for us to completely disregard the basic biology of the two different species, but the differences between C. neoformans and C. gattii strains are moving targets. As this study demonstrates, the differences in virulence between species and strains are measurable but the stability of these differences and their relevance to clinical disease are less certain (12). At present, a clinician managing an individual case of cryptococcosis probably does not need to know the identity of the infecting species and the Infectious Diseases Society of America guidelines for cryptococcosis treatment are the same, regardless (13).
The second principle so elegantly described by this work is the importance of the site of infection. Since its first description in 1914, clinicians have known that Cryptococcus has a unique predisposition to invade the human central nervous system, and today it is responsible for an estimated one million cases of cryptococcal meningitis per year worldwide (14), making it a leading cause of meningitis. How it survives and migrates to sites of infection continues to fascinate and perplex pathobiologists, but molecular pathogenesis studies are beginning to provide insights into the sugar-coated yeast’s modus operandi. Our group has shown that even yeast survival in the relatively benign cerebrospinal fluid is controlled by multiple genes, including Ena1, Rub1, and Pik1 (15). Furthermore, the stressors provided by its immediate environment require it to utilize different pathways of metabolism. For instance, its use of fundamental processes of carbon and energy metabolism, glycolysis and gluconeogenesis, vary in their importance depending on whether it resides in the lung or the brain (16). Ngamskulrungroj et al. observed differences in survival rates in blood between C. neoformans and C. gattii.
These yeasts must be able to live and grow within the harsh, inhospitable host environment as temperature, nutrition, and other innate factors work to eradicate it. Our clinical epidemiology studies have suggested that the two species prefer different sites of infection: C. neoformans more commonly causes disease in the central nervous system, and C. gattii more frequently produces pulmonary infections (17, 18). This predilection seems to be supported by the controlled study by Ngamskulrungroj et al. However, it needs to be carefully emphasized that C. gattii can do anything that C. neoformans can do and they can both do it in the same populations and at the same infectious site. It would be wrong to categorize one species as a pulmonary pathogen and the other as a central nervous system pathogen or one species as the immunosuppressant organism and the other as the immunocompetent organism. Pathobiology is simply not that simple.
Finally, there is the question of how each species, C. gattii or C. neoformans, interacts with the human immune system, a question researchers have been addressing for the last 30 years (19). In fact, there has been great progress. On a simple basis, we understand the importance of cell-mediated host immunity through our clinical observations of risk groups such as AIDS patients, transplant recipients, and patients undergoing corticosteroid and anti-tumor necrosis factor antibody treatments and basic scientific studies that are validated by elegant and detailed immunological studies of both cell-mediated and humoral immunity. However, as this study clearly illustrates, our understanding remains imprecise despite these foundation studies and insights. The study by Ngamskulrungroj et al. suggests that C. gattii produces an immune response that is different from and more protective against infection than that produced by C. neoformans (1). On the other hand, a recent study with a different set of mice and strains found that C. neoformans appeared to elicit a more robust and protective immune response than C. gattii (20). Determination of the details of how strains and, specifically, species, with their structurally different protective capsules and their ability to even produce different metabolites that directly impact immune cell responses, present themselves to the host (21) requires further studies for better insights. However, findings in this report challenge us to obtain a greater understanding of the complex interactions between hosts and yeasts at the site of infection.
After over a century of studying cryptococcosis as a fungal disease in humans, we have outstanding molecular tools, robust animal models, and basic understandings of pathology from both the yeast and host perspectives. However, we still do not have all the answers. From its humble beginning as an isolate obtained by Francesco Sanfelice in peach juice in 1894 and its link to a single case of human disease a year later, this yeast has evolved into a major human pathogen which kills over half a million individuals per year (14). Work to understand and control cryptococcosis must continue. The sugar-coated yeast, whether it is C. neoformans or C. gattii, is flexible, complex, and deadly and deserves our respect and attention. To emphasize its mystery, perhaps rather than Cryptococcus, this “cryptic” yeast should be referred to as “Cryptic-coccus.” Many of its disease features are still hidden from us.

REFERENCES

1.
Ngamskulrungroj P, Chang Y, Sionov E, and Kwon-Chung KJ. 2012. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3(3):e00103-12.
2.
Kwon-Chung KJ and Varma A. 2012. Do major species concepts support one, two or more species with Cryptococcus neoformans? FEMS Yeast Res. 6:574–587.
3.
D’Souza CA et al. 2011. Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. mBio 2(1):e00342-10.
4.
Loftus BJ et al. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307:1321–1324.
5.
Ngamskulrungroj P et al. 2009. The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect. Immun. 77:4584–4596.
6.
Ngamskulrungroj P, Price J, Sorrell T, Perfect JR, and Meyer W. 2011. Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver Island outbreak strains. PLoS One 6:e16076.
7.
Fraser JA et al. 2005. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437:1360–1364.
8.
Hu G, Wang J, and Choi J. 2011. Chromosome copy number variation Cryptococcus neoformans influences virulence and occurs in isolates from AIDS patients. BMC Genomics 12:526.
9.
Morrow CA, Lee RI, and Chow EW. 2012. A unique chromosomal rearrangement in the Cryptococcus neoformans var. grubii type strain enhances key phenotypes associated with virulence. mBio 3(2):e00310-11.
10.
Semighini CP, Averett AF, Perfect JR, and Heitman J. 2012. Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. PLoS Pathog. 7:e1002364.
11.
Sionov E, Lee H, Chang YC, and Kwon-Chung KJ. 2010. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6:e1000848.
12.
Chen S et al. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin. Infect. Dis. 31:499–508.
13.
Perfect JR et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291–322.
14.
Park BJ et al. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530.
15.
Lee A et al. 2010. Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect. Immun. 78:4213–4225.
16.
Price MS et al. 2011. Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. mBio 2(3):e00103-11.
17.
Galains E and MacDougall L. 2012. Epidemiology of Cryptococcus gattii, British Columbia, Canada 1999–2007. Emerg. Infect. Dis. 16:251–257.
18.
Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, and Casadevall A. 2012. Clinical perspectives on Cryptococcus neoformans and Cryptococcus gattii: implications for diagnosis and management, p 595–606. American Society for Microbiology, Washington, DC.
19.
Shoham S and Levitz SM. 2005. The immune response to fungal infections. Br. J. Haematol. 129:569–582.
20.
Cheng PY, Sham A, and Kronstad JW. 2012. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect. Immun. 77:4284–4294.
21.
Wright L et al. 2002. Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes Infect. 4:1427–1438.

Information & Contributors

Information

Published In

cover image mBio
mBio
Volume 3Number 431 August 2012
eLocator: 10.1128/mbio.00165-12

History

Published online: 10 July 2012

Contributors

Author

John R. Perfect
Duke University Medical Center, Durham, North Carolina, USA

Notes

Address correspondence to John R. Perfect, [email protected].

Metrics & Citations

Metrics

Note: There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.

Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy